Drive global lifecycle strategy and cross-functional leadership for daraxonrasib to optimize oncology portfolio value.

• Lifecycle & Commercial Strategy
• Define and continuously refine the global lifecycle strategy for daraxonrasib across indications, lines of therapy, and combination opportunities.
• Identify cross-indication synergies, expansion pathways, and systemic program risks, drive mitigation strategies.
• Translate clinical data, competitive insights, and regulatory strategy into differentiated commercial positioning and value propositions.
• Ensure alignment between disease area strategy and molecule-level priorities.
• Cross-Functional Integration
• Architect and lead the Lifecycle Team (LCT) and working groups in a fit-for-purpose manner.
• Partner closely with Clinical Development, Regulatory, Medical Affairs, Market Access, and Portfolio teams to ensure integrated decision-making.
• Serve as a core member of governance forums, preparing recommendations and driving enterprise alignment.
• Escalate major strategic decisions with clearly articulated recommendations aligned with portfolio principles.
• Portfolio & Financial Stewardship
• Develop and own the strategic roadmap, milestones, financial targets, and key objectives of the asset.
• Balance long-term strategic priorities with short-term operational execution.
• Organizational Leadership
• Build, lead, and develop a high-performing, highly cross-functional lifecycle team, driving alignment and accountability across team members, senior leaders and functions to execute an integrated global lifecycle strategy.
• Contribute to the maturation and evolution of the Lifecycle function by establishing scalable frameworks, best practices, and operating models that enable integrated, end-to-end asset strategy across the portfolio
• Foster a collaborative, cross-functional culture that embraces innovation, agility, and accountability.
• Serve as a trusted advisor to executive leadership on lifecycle optimization and commercial value creation.